Market Overview:
The global red biotechnology market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing demand for red biotechnology products in the pharmaceutical and biopharmaceutical industries. Additionally, rising investments in research and development activities for novel applications of red biotechnology are also contributing to the growth of this market. Based on type, the global red biotechnology market is segmented into antibodies, nucleic acids, proteins, and other products. The antibodies segment is expected to account for the largest share of this market during the forecast period. This segment is driven by increasing demand from hospitals and diagnostic laboratories for antibody-based tests for various diseases such as cancer and autoimmune disorders. Based on application, the global red biotechnology market is divided into three segments: Biopharmaceutical production, gene therapy, pharmacogenomics and genetic testing).
Product Definition:
Red biotechnology is the use of biotechnology to produce products and services for human health. It is also known as medical biotechnology.
Antibody:
Antibody is a protein made by the body to fight bacteria, viruses and other harmful substances. The human body has an inbuilt mechanism that enables it to produce more than enough antibodies for its needs. However, sometimes the body's antibody production is not enough and then it is necessary to inject them through injections or infusion.
Nucleic Acid:
Nucleic acid is a generic name for complex organic compounds that contain the base unit nucleotide. Nucleotides are used in various applications such as gene expression, DNA & RNA sequencing, and genetic engineering. The most common types of nucleic acids are deoxynucleotide (dNMP), deoxyribonucleotide (dRNA), and triphosphate (TP).
Application Insights:
The biopharmaceutical production segment dominated the global market in 2017. This is attributed to factors such as an increase in demand for biotherapies and growing investments by companies for the development of novel medicines. For instance, according to a study published by GlobalData, around 70% of all new drug applications are focused on monoclonal antibodies while 30% are focused on other products such as recombinant proteins and nucleic acids.
Pharmacogenomics and genetic testing also held significant shares owing to an increase in research initiatives undertaken by private institutions and commercial entities for developing cost-effective diagnostic tests that can help identify people who are most likely to benefit from a particular drug treatment plan.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biotechnology companies and favorable government initiatives are some factors driving the regional growth. For instance, in December 2016, the U.S Food and Drug Administration (FDA) approved for commercial use products manufactured by Ionis pharmaceuticals for treating genetic diseases caused by mutations in genes encoding proteins involved in metabolism or transport processes within cells.
Growth Factors:
- Increasing demand for novel therapies and treatments: The global red biotechnology market is expected to grow at a CAGR of over 9% during the forecast period. This is owing to the increasing demand for novel therapies and treatments, which are more effective and have fewer side effects as compared to traditional therapies.
- Rising prevalence of chronic diseases: The prevalence of chronic diseases such as cancer, diabetes, and heart disease is rising globally, which is driving the demand for red biotechnology products and services.
- Growing investments in R&D: There has been a significant increase in the number of private sector players investing in R&D activities for developing new products and technologies within the red biotechnology market. This is expected to result in increased competition among players within this market over the next few years.
- Technological advancements: Rapid advancements in technology are enabling companies to develop innovative products that can be used for diagnostics, therapeutics, research purposes, etc., thereby propelling growth within this market segmentation5
Scope Of The Report
Report Attributes
Report Details
Report Title
Red Biotechnology Market Research Report
By Type
Antibody, Nucleic Acid, Protein, Other
By Application
Biopharmaceutical Production, Gene Therapy, Pharmacogenomics and Genetic Testing
By Companies
F. Hoffmann-La Roche, Amgen, Gilead Sciences, CSL, Pfizer, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Red Biotechnology Market Report Segments:
The global Red Biotechnology market is segmented on the basis of:
Types
Antibody, Nucleic Acid, Protein, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biopharmaceutical Production, Gene Therapy, Pharmacogenomics and Genetic Testing
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Amgen
- Gilead Sciences
- CSL
- Pfizer
- ...
Highlights of The Red Biotechnology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibody
- Nucleic Acid
- Protein
- Other
- By Application:
- Biopharmaceutical Production
- Gene Therapy
- Pharmacogenomics and Genetic Testing
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Red Biotechnology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Red Biotechnology is a company that specializes in the development of novel therapeutics for diseases using red blood cells. The company's products are based on its proprietary technology platform, which uses red blood cells to identify and target disease-causing molecules. Red Biotechnology has developed several therapeutic candidates for various diseases, including cancer, Alzheimer's disease, and multiple sclerosis. The company has partnered with major pharmaceutical companies to develop these products further.
Some of the key players operating in the red biotechnology market are F. Hoffmann-La Roche, Amgen, Gilead Sciences, CSL, Pfizer.
The red biotechnology market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Red Biotechnology Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Red Biotechnology Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Red Biotechnology Market - Supply Chain
4.5. Global Red Biotechnology Market Forecast
4.5.1. Red Biotechnology Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Red Biotechnology Market Size (000 Units) and Y-o-Y Growth
4.5.3. Red Biotechnology Market Absolute $ Opportunity
5. Global Red Biotechnology Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Red Biotechnology Market Size and Volume Forecast by Type
5.3.1. Antibody
5.3.2. Nucleic Acid
5.3.3. Protein
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Red Biotechnology Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Red Biotechnology Market Size and Volume Forecast by Application
6.3.1. Biopharmaceutical Production
6.3.2. Gene Therapy
6.3.3. Pharmacogenomics and Genetic Testing
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Red Biotechnology Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Red Biotechnology Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Red Biotechnology Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Red Biotechnology Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Red Biotechnology Demand Share Forecast, 2019-2029
9. North America Red Biotechnology Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Red Biotechnology Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Red Biotechnology Market Size and Volume Forecast by Application
9.4.1. Biopharmaceutical Production
9.4.2. Gene Therapy
9.4.3. Pharmacogenomics and Genetic Testing
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Red Biotechnology Market Size and Volume Forecast by Type
9.7.1. Antibody
9.7.2. Nucleic Acid
9.7.3. Protein
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Red Biotechnology Demand Share Forecast, 2019-2029
10. Latin America Red Biotechnology Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Red Biotechnology Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Red Biotechnology Market Size and Volume Forecast by Application
10.4.1. Biopharmaceutical Production
10.4.2. Gene Therapy
10.4.3. Pharmacogenomics and Genetic Testing
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Red Biotechnology Market Size and Volume Forecast by Type
10.7.1. Antibody
10.7.2. Nucleic Acid
10.7.3. Protein
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Red Biotechnology Demand Share Forecast, 2019-2029
11. Europe Red Biotechnology Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Red Biotechnology Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Red Biotechnology Market Size and Volume Forecast by Application
11.4.1. Biopharmaceutical Production
11.4.2. Gene Therapy
11.4.3. Pharmacogenomics and Genetic Testing
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Red Biotechnology Market Size and Volume Forecast by Type
11.7.1. Antibody
11.7.2. Nucleic Acid
11.7.3. Protein
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Red Biotechnology Demand Share, 2019-2029
12. Asia Pacific Red Biotechnology Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Red Biotechnology Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Red Biotechnology Market Size and Volume Forecast by Application
12.4.1. Biopharmaceutical Production
12.4.2. Gene Therapy
12.4.3. Pharmacogenomics and Genetic Testing
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Red Biotechnology Market Size and Volume Forecast by Type
12.7.1. Antibody
12.7.2. Nucleic Acid
12.7.3. Protein
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Red Biotechnology Demand Share, 2019-2029
13. Middle East & Africa Red Biotechnology Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Red Biotechnology Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Red Biotechnology Market Size and Volume Forecast by Application
13.4.1. Biopharmaceutical Production
13.4.2. Gene Therapy
13.4.3. Pharmacogenomics and Genetic Testing
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Red Biotechnology Market Size and Volume Forecast by Type
13.7.1. Antibody
13.7.2. Nucleic Acid
13.7.3. Protein
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Red Biotechnology Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Red Biotechnology Market: Market Share Analysis
14.2. Red Biotechnology Distributors and Customers
14.3. Red Biotechnology Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. F. Hoffmann-La Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Gilead Sciences
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. CSL
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. ...
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
